Pressure to reduce time-to-market and improve overall business performance has forced pharmaceutical and biotechnology companies to analyse existing drug development strategies, and explore new market opportunities in the Asia Pacific region. The aggressive growth of Asia’s pharmaceutical and biotechnology industry is outpacing performance in other parts of the world. This can be attributed to the increased number of global partnerships, collaborations and outsourcing from the US and European markets. Pharmaceutical and biotechnology executives in turn are focusing on niches in areas such as vaccines, information and bioinformatics, natural therapies, stem cells and contract research in efforts to remain competitive. These strategic moves will further contribute to the development of Asia’s biotechnology and pharmaceutical companies as innovative, globally competitive organisations. Competition is tight, as Asian governments are making drug development their strategic priority and are increasing the funding they are providing.
The Drug Development Asia Summit provides a platform for Asia’s leading pharmaceutical executives to prepare for future growth challenges and align themselves with the global strategy. The Drug Development Asia Summit is an exclusive gathering that will bring together senior-level pharmaceutical and biotechnology executives with a select and diversified group of leading-edge Solution Providers to converge over these vital industry issues. Within a focused and professional environment, The Drug Development Asia Summit will seamlessly integrate oneon- one meetings and informal networking with leisure activities. Qualified invitation-only Delegates will meet with Solution Provider representatives via pre-scheduled and tailored one-on-one meetings.